Literature DB >> 27595627

[Colpocleisis: guidelines for clinical practice].

X Deffieux1, T Thubert2, L Donon3, J-F Hermieu4, L Le Normand5, C Trichot6.   

Abstract

OBJECTIVE: To provide clinical practice guidelines (CPGs) based on the best evidence available (level of evidence (LE)), concerning colpocleisis as a surgical treatment of pelvic organ prolapse.
METHODS: This article concern a systematically review of the literature concerning colpocleisis (obliterative surgery).
RESULTS: At short term follow-up, colpocleisis is associated with an anatomical success rate of 98 % (LE3) and a subjective success rate of 93% (LE3). A decrease in genital, urinary and anorectal symptoms and an enhancement of quality of life are observed in most women following colpocleisis (LE4). At mid-term (1 to 3 years) follow-up, patients' satisfaction ("satisfied" or "very satisfied" ranges from 85 to 100% (LE3)). At long-term follow-up, regret rate (women who regret having had the surgery) is 5% (LE4). In women over 80 years old, colpocleisis is associated with a decrease in per-and post-operative complication rates when compare to other surgical techniques used for pelvic organ prolapse surgery (LE2).
CONCLUSION: Colpocleisis is a valid surgical option for elderly patients with pelvic organ prolapse surgery, and who are definitely permanently sexually inactive (Grade C).
© 2016 Published by Elsevier Masson SAS. © 2016 Elsevier Masson SAS. Tous droits réservés.

Entities:  

Keywords:  Colpocleisis; Colpocléisis; Genital prolapse; Guidelines; Prolapsus génital; Recommandations; Surgical treatment; Traitement chirurgical

Mesh:

Year:  2016        PMID: 27595627     DOI: 10.1016/S1166-7087(16)30429-8

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  1 in total

1.  Quality of life following vaginal reconstructive versus obliterative surgery for treating advanced pelvic organ prolapse.

Authors:  Alin Petcharopas; Supreeya Wongtra-Ngan; Orawee Chinthakanan
Journal:  Int Urogynecol J       Date:  2018-01-27       Impact factor: 2.894

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.